RESUMO
OBJECTIVE: The prognostic impact of early stages of histologically confirmed alcoholic liver disease is uncertain. Our aim was to determine the risk of cirrhosis and premature death, and identify prognostic markers, in patients with biopsy-proven alcoholic steatohepatitis - and to compare prognosis in patients with alcoholic pure fatty liver and the general population. MATERIAL AND METHODS: Patients with biopsy-proven alcoholic fatty liver disease diagnosed during 1976-1987 were identified. Data were collected from medical records, the Danish National Patient Registry and the Registry of Causes of Death. All biopsies were re-examined and morphological findings assessed. A reference cohort matched for age and gender was created. Cox proportional hazard models adjusted for age and gender were used to analyse differences in mortality and cirrhosis development, as well as the prognostic impact of histological and biochemical parameters. RESULTS: Two hundred and twenty-five patients with fatty liver and 111 with steatohepatitis were followed for median 13 and 9.7 years, respectively. There was a significantly higher risk of developing cirrhosis amongst patients with steatohepatitis compared to both patients with fatty liver (p < 0.001) and the reference cohort (p < 0.001). Mortality was significantly higher in patients with steatohepatitis compared to patients with fatty liver (p = 0.046) and the general population (p < 0.001). No histological or biochemical parameters with prognostic significance for mortality were identified. CONCLUSION: Presence of steatohepatitis indicates an increased risk of cirrhosis and premature death. However, none of the histological parameters defining steatohepatitis can independently identify patients at risk for premature death.
Assuntos
Progressão da Doença , Fígado Gorduroso Alcoólico/mortalidade , Fígado Gorduroso Alcoólico/patologia , Cirrose Hepática/epidemiologia , Mortalidade Prematura , Adulto , Idoso , Biópsia , Causas de Morte , Dinamarca , Feminino , Humanos , Fígado/patologia , Cirrose Hepática/patologia , Masculino , Pessoa de Meia-Idade , Prognóstico , Modelos de Riscos Proporcionais , Sistema de Registros , Estudos Retrospectivos , Fatores de RiscoRESUMO
OBJECTIVE: Continuous infusion of levodopa carbidopa intestinal gel (LCIG) is associated with a significant improvement in the symptoms and quality of life of selected patients with advanced Parkinson's disease. Percutaneous endoscopic gastrostomy with jejunal extension (PEG/J) was first described in 1998 and has become the most common and standard technique for fixing the tubing in place for LCIG infusion. MATERIAL AND METHODS: A workshop was held in Stockholm, Sweden, to discuss the PEG/J placement for the delivery of LCIG in Parkinson's disease patients with the primary goal of providing guidance on best practice for the Nordic countries. RESULTS: Suggested procedures for preparation of patients for PEG/J placement, aftercare, troubleshooting and redo-procedures for use in the Nordic region are described and discussed. CONCLUSIONS: LCIG treatment administered through PEG/J-tubes gives a significant increase in quality of life for selected patients with advanced Parkinson's disease. Although minor complications are common, serious complications are infrequent, and the tube insertion procedures have a good safety record. Further development of delivery systems and evaluation of approaches designed to reduce the demand for redo endoscopy are required.
Assuntos
Antiparkinsonianos/administração & dosagem , Carbidopa/administração & dosagem , Gastrostomia/métodos , Levodopa/administração & dosagem , Doença de Parkinson/cirurgia , Géis , Humanos , Doença de Parkinson/terapia , Seleção de Pacientes , Complicações Pós-Operatórias , Qualidade de Vida , Países Escandinavos e NórdicosRESUMO
BACKGROUND & AIMS: Histologic analysis of liver biopsy specimens allows for grading and staging of nonalcoholic fatty liver disease (NAFLD). We performed a longitudinal study to investigate the long-term prognostic relevance of histologic features for patients with NAFLD. METHODS: We performed a retrospective analysis of 619 patients diagnosed with NAFLD from 1975 through 2005 at medical centers in the United States, Europe, and Thailand. Patients underwent laboratory and biopsy analyses, and were examined every 3-12 months after their diagnosis. Outcomes analyzed were overall mortality, liver transplantation, and liver-related events. Cumulative outcomes were compared by log-rank analysis. Cox proportional-hazards regression was used to estimate adjusted hazard ratios (HRs). Time at risk was determined from the date of liver biopsy to the date of outcome or last follow-up examination. RESULTS: Over a median follow-up period of 12.6 years (range, 0.3-35.1 y), 193 of the patients (33.2%) died or underwent liver transplantation. Features of liver biopsies significantly associated with death or liver transplantation included fibrosis stage 1 (HR, 1.88; 95% confidence interval [CI], 1.28-2.77), stage 2 (HR, 2.89; 95% CI, 1.93-4.33), stage 3 (HR, 3.76; 95% CI, 2.40-5.89), and stage 4 (HR, 10.9; 95% CI, 6.06-19.62) compared with stage 0, as well as age (HR, 1.07; 95% CI, 1.05-1.08), diabetes (HR, 1.61; 95% CI, 1.13-2.30), current smoking (HR, 2.62; 95% CI, 1.67-4.10), and statin use (HR, 0.32; 95% CI, 0.14-0.70). Twenty-six patients (4.2%) developed liver-related events; fibrosis stage 3 (HR, 14.2; 95% CI, 3.38-59.68) and stage 4 (HR, 51.5; 95% CI, 9.87-269.2) compared with stage 0, were associated significantly with the events. Patients with fibrosis, regardless of steatohepatitis or NAFLD activity score, had shorter survival times than patients without fibrosis. CONCLUSIONS: In a longitudinal study of patients with NAFLD, fibrosis stage, but no other histologic features of steatohepatitis, were associated independently with long-term overall mortality, liver transplantation, and liver-related events.
Assuntos
Cirrose Hepática/epidemiologia , Cirrose Hepática/patologia , Transplante de Fígado/mortalidade , Fígado/patologia , Hepatopatia Gordurosa não Alcoólica , Adulto , Fatores Etários , Biópsia , Diabetes Mellitus/epidemiologia , Europa (Continente) , Feminino , Seguimentos , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Hepatopatia Gordurosa não Alcoólica/complicações , Hepatopatia Gordurosa não Alcoólica/patologia , Hepatopatia Gordurosa não Alcoólica/fisiopatologia , Hepatopatia Gordurosa não Alcoólica/terapia , Prognóstico , Estudos Retrospectivos , Fatores de Risco , Índice de Gravidade de Doença , Fumar/epidemiologia , Tailândia , Fatores de Tempo , Estados UnidosRESUMO
BACKGROUND: Bacterial translocation (BT) may cause infections, in particular, spontaneous bacterial peritonitis (SBP). In the absence of overt infection, BT may further stimulate the immune system and contribute to haemodynamic alterations and complications. Bacterial DNA (bDNA) is claimed to be a promising surrogate marker for BT, although its clinical relevance has been questioned. MATERIALS AND METHODS: In 38 cirrhotic patients with and without SBP, bDNA in blood and ascites were assessed by 16S rDNA quantitative PCR. Levels of lipopolysaccharide-binding protein in plasma and highly sensitive C-reactive protein, tumour necrosis factor-α, soluble urokinase plasminogen activating receptor, interleukin-6, interleukin 8, interferon-γ inducible protein-10 and vascular endothelial growth factor in plasma and ascites were measured by multiplex cytokine and ELISA assays. RESULTS: In patients without signs of SBP or positive cultures, we found a high frequency of bDNA but low concordance of bDNA between blood and ascites. Markers of inflammation were not significantly different between blood bDNA-positive (22%), ascites bDNA-positive (52%), and bDNA-negative patients. The 16S rDNA PCR failed to show bDNA in two out of six samples with SBP. Sequencing of positive samples did not determine the source of bDNA. CONCLUSION: bDNA as assessed by this PCR method was largely unrelated to markers of inflammation and does not seem to be of clinical value in the diagnosis of SBP. According to our results, bDNA is not a reliable marker of BT.
Assuntos
Ascite/etiologia , Bactérias/genética , Infecções Bacterianas/etiologia , Translocação Bacteriana , DNA Bacteriano/genética , Mediadores da Inflamação/sangue , Cirrose Hepática/complicações , Peritonite/etiologia , RNA Ribossômico 16S/genética , Ascite/sangue , Ascite/diagnóstico , Ascite/imunologia , Ascite/microbiologia , Líquido Ascítico/imunologia , Líquido Ascítico/microbiologia , Bactérias/classificação , Infecções Bacterianas/sangue , Infecções Bacterianas/diagnóstico , Infecções Bacterianas/imunologia , Infecções Bacterianas/microbiologia , Biomarcadores/sangue , DNA Bacteriano/sangue , Feminino , Humanos , Cirrose Hepática/sangue , Cirrose Hepática/diagnóstico , Cirrose Hepática/imunologia , Cirrose Hepática/microbiologia , Masculino , Pessoa de Meia-Idade , Noruega , Peritonite/sangue , Peritonite/diagnóstico , Peritonite/imunologia , Peritonite/microbiologia , Valor Preditivo dos Testes , Estudos Prospectivos , RNA Ribossômico 16S/sangue , Reação em Cadeia da Polimerase em Tempo Real , Reprodutibilidade dos Testes , Ribotipagem/métodosRESUMO
INTRODUCTION: Non-alcoholic fatty liver disease encompasses a spectrum of histological lesions ranging from steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. Simple steatosis is generally benign, while NASH can progress to severe liver disease. The aim of the present study was to quantify the number of patients with NASH and assess the prognosis associated with the condition in a large Danish referral centre for liver disease. MATERIAL AND METHODS: Through the pathology archives at Hvidovre Hospital, 348 patients with steatohepatitis diagnosed during the 1976-1987-period were identified. Data were systematically collected by review of available medical records. These data were supplemented by data from the Danish National Hospital Registry and the Registry of Causes of Death. RESULTS: A total of 100 patients referred from other hospitals were excluded as their records were missing and 236 patients were excluded, mainly due to a history of alcohol abuse; this left 14 patients to constitute the study population. At the end of the follow-up period which had a median duration of 16.7 years, ten of the patients had died: four of cardiovascular disease, four of extra-hepatic neoplasm and two of unknown causes. There were no liver-related deaths and only one patient developed cirrhosis. CONCLUSION: In a specialised referral centre, only few patients were diagnosed with NASH 25-30 years ago and those who were identified had a low risk of progression to cirrhosis and premature death. FUNDING: The local research council and the foundation for the study of liver diseases at Hvidovre Hospital provided funding for this study. TRIAL REGISTRATION: not relevant.
Assuntos
Fígado Gorduroso , Cirrose Hepática/epidemiologia , Cirrose Hepática/patologia , Fígado/patologia , Adulto , Idoso , Consumo de Bebidas Alcoólicas , Biópsia , Dinamarca/epidemiologia , Progressão da Doença , Fígado Gorduroso/epidemiologia , Fígado Gorduroso/etiologia , Fígado Gorduroso/patologia , Fígado Gorduroso/fisiopatologia , Fígado Gorduroso/psicologia , Feminino , Humanos , Incidência , Cirrose Hepática/etiologia , Cirrose Hepática/fisiopatologia , Masculino , Registros Médicos Orientados a Problemas/estatística & dados numéricos , Pessoa de Meia-Idade , Hepatopatia Gordurosa não Alcoólica , Prevalência , PrognósticoRESUMO
The risk of progression to cirrhosis and death in patients with pure alcoholic (AFLD) and non-alcoholic steatosis (NAFLD) has only sparsely been studied. The aims of the present long-term follow-up study were to analyze for risks of progression to cirrhosis and death in a cohort of patients with histologically verified 'pure fatty liver'. 247 patients with biopsy verified AFLD and 170 patients with NAFLD without inflammation were included in the period from 1978 to 1987. Patients in the study cohort were linked through their personal identification number to The National Patient Registry (LPR) and The Causes of Death Registry. All admissions, discharge diagnoses, and causes of death were obtained from January 1, 1977 until death (2004) or December 31, 1999 in the registries. Surviving patients were offered a clinical follow-up in 2004. Survival was observed to be significantly higher (p < 0.01) in NAFLD for men as well as for women, which was not different from the Danish age- and gender-matched population. Two (1.2%) patients with NAFLD developed cirrhosis, while 54 patients (21.9%) with AFLD developed cirrhosis. The degree of steatosis was the only histological parameter significantly associated with premature death in AFLD, but not in NAFLD patients. Risk of progression to cirrhosis and time to development was significantly associated to being of female gender. In conclusion, for patients with NAFLD, survival was good, while patients with AFLD had excess in mortality and risk of development of cirrhosis, which was associated with the degree of steatosis in the index biopsy and being of female gender.
Assuntos
Fígado Gorduroso/patologia , Alcoolismo/complicações , Biópsia , Causas de Morte , Fígado Gorduroso/complicações , Feminino , Seguimentos , Humanos , Estimativa de Kaplan-Meier , Fígado/patologia , Masculino , Hepatopatia Gordurosa não Alcoólica , Modelos de Riscos Proporcionais , Fatores de TempoRESUMO
OBJECTIVE: There is increasing focus on non-alcoholic fatty liver disease (NAFLD). The aim of the present study was to conduct a long-term clinical follow-up of patients with biopsy-confirmed fatty liver without inflammation or significant fibrosis (pure fatty liver), to analyse for potential risk factors at the time of index liver biopsy important for survival and the development of cirrhosis and to describe the causes of death. MATERIAL AND METHODS: Patients were linked through their personal identification number to the Danish National Registry of Patients and the Register of Causes of Death. All admissions, discharge diagnoses and causes of death during follow-up were collected. All surviving patients were invited to a clinical follow-up. RESULTS: The follow-up period was 20.4 and 21.0 years, respectively, for the NAFLD and alcoholic fatty liver disease (AFLD) groups. Two NAFLD patients (1.2%) developed cirrhosis during the follow-up period versus 54 (22%) AFLD patients. Sixty-four percent of 178 surviving patients out of an original cohort of 417 patients attended the clinical follow-up. In NAFLD patients, none of the risk factors studied was significant in relation to the risk of death. Patients with AFLD died primarily from cirrhosis and other alcohol-related disorders, whereas in patients with NAFLD the main causes of death were cardiovascular disease and cancer. CONCLUSIONS: For patients with pure non-alcoholic fatty liver, survival was good and independent of the histological, clinical and biochemical characteristics at the time of biopsy; the main causes of death were cardiovascular disease and cancer.
Assuntos
Fígado Gorduroso/mortalidade , Fígado Gorduroso/patologia , Fígado/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Biópsia , Causas de Morte , Fígado Gorduroso Alcoólico/mortalidade , Fígado Gorduroso Alcoólico/patologia , Feminino , Seguimentos , Humanos , Cirrose Hepática , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Fatores de TempoRESUMO
OBJECTIVE: The clinical-pathological spectrum of fatty liver ranges from simple steatosis to end-stage fibrotic liver disease. However, no histological characteristics have been identified that can predict progression from pure steatosis to fibrotic liver disease in non-alcoholic fatty liver disease. The objective of this study was to investigate whether histological characteristics in patients with fatty liver without inflammation could predict mortality or development of cirrhosis. MATERIAL AND METHODS: A total of 417 patients had a liver biopsy performed, which showed fatty liver without inflammation. The population consisted of 170 non-alcoholic and 247 alcoholic fatty liver patients. The study cohort was linked through their unique personal identification number to The National Registry of Patients and the nationwide Registry of Causes of Death. RESULTS: Median follow-up time was 19.9 years in the non-alcoholic group and 12.8 years in the alcoholic group. Overall mortality in the non-alcoholic group was not related to morphological findings in the index liver biopsy. Mortality was significantly (p < 0.05) higher in alcoholic patients with severe steatosis. One non-alcoholic patient (0.6%) developed cirrhosis versus 54 alcoholic patients (22%) during the follow-up period. CONCLUSIONS: In patients with non-alcoholic fatty liver without inflammation, patients at risk for premature death cannot be identified by histological characteristics in the index liver biopsy. Patients with alcoholic fatty liver have a high risk for development of cirrhosis and increased mortality with the severity of steatosis in the index liver biopsy.